A Scientific Statement From the AHA on CV Risk in Nonalcoholic Fatty Liver Disease
The American Heart Association has issued a scientific statement regarding the relationship between nonalcoholic fatty liver disease and cardiovascular risk.
The American Heart Association has issued a scientific statement regarding the relationship between nonalcoholic fatty liver disease and cardiovascular risk.
Researchers examined the association between initiating statin therapy and the risk for HCC in patients with NAFLD.
Researchers analyzed the relationship between metabolic dysfunction-associated fatty liver disease and the risk for colon cancer.
Investigators assessed the effects of different levels of physical activity on the prevalence of nonalcoholic fatty liver disease and its association with metabolic health.
Researchers evaluated the effects of statin use on cancer mortality in patients with nonalcoholic fatty liver disease.
There is a bidirectional association between nonalcoholic fatty liver disease and psoriasis, especially for patients younger than 40 years.
Nonalcoholic fatty liver disease is associated with a higher risk for severe hypoglycemia in patients with type 2 diabetes.
Investigators examined the effects of certain antihyperglycemic drugs as treatment for NAFLD or NASH in patients with or without type 2 diabetes.
Investigators assessed baseline characteristics and long-term outcomes of White patients classified as lean with nonalcoholic fatty liver disease.
Investigators assessed the efficacy and safety of duodenal mucosal resurfacing vs a sham endoscopic procedure in patients with type 2 diabetes with or without NAFLD.